A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
Solving challenges in manufacturing, construction, and infrastructure with proprietary AI that leverages even limited data. A startup supporting operational efficiency and labor savings, aiming for a future where humans and AI coexist.
B-Lab is a biotechnology venture originating from Konan University, engaged in the production and sales of β-1,3-1,6-glucan nanoparticles and betaine-derived aqueous solutions. Based on biomimetic chemistry, these products drive the development of next-generation, safe, and environmentally harmonized biomaterial technologies applicable to the food, cosmetic, pharmaceutical, agricultural, and chemical industries.
A startup developing a drug discovery platform capable of simultaneously measuring intracellular signals over time using proprietary technology, addressing multi-factor and multi-target drug discovery. Accelerating efficient and comprehensive new drug development through high-dimensional data and AI analysis.
Drug development for neurodegenerative diseases.